WEBULL
WebtradeDownload

Bio-Techne (TECH) Stock Trades Above Fair Value On Cash Flow Estimates

Simply Wall St · 23h ago

Bio-Techne has delivered positive returns over the past year, yet the longer track record tells a very different story. That naturally raises the question of whether the current share price lines up with the cash the business can generate. Using a Discounted Cash Flow (DCF) lens, the focus turns firmly to the stream of cash flows that might support, or challenge, what the market is paying today.

  • Over 5 years, Bio-Techne shareholders have seen the stock decline 40.8%. This puts the spotlight on whether the cash the business can produce now justifies sticking with it at around today's level.
  • The group’s model in life-sciences tools depends heavily on converting research demand into steady, high-quality cash inflows. Any change in pricing power or cost discipline can directly shift what those future cash streams are worth today.
  • What if you looked at Bio-Techne through its earnings instead? See what Bio-Techne's 62.7x P/E says about the price.

The issue now is whether Bio-Techne's current market value is supported by the cash flows implied by its intrinsic value estimate under the Discounted Cash Flow (DCF) approach.

If you want other ideas where price is weighed directly against cash generation, a focused screener built around 35 high quality undervalued stocks can be a useful secondary starting point for your research.

Is Bio-Techne Getting Expensive on Cash Flow?

The Discounted Cash Flow (DCF) model here looks at the cash Bio-Techne can return to shareholders over time and then pulls those future dollars back into today’s terms. Bio-Techne generated about $250.6 million of free cash flow over the last twelve months, and the model assumes that this figure continues to rise through the next decade rather than shrink. That path, from current free cash generation into higher forecast levels by 2030, underpins the 2 Stage Free Cash Flow to Equity framework used.

Analyst inputs support a growing free cash flow profile, with projected annual figures stepping up into the $400 million range by 2030, followed by a transition into slower estimated expansion beyond that point. When those cash streams are discounted and compared with the current share price of $72.66, the Discounted Cash Flow (DCF) output suggests Bio-Techne’s estimated intrinsic value is meaningfully below where the stock trades today, which is an important context check for anyone focusing on cash returns. Find out what Bio-Techne could be worth using our Discounted Cash Flow (DCF) estimate.

The Bio-Techne Narrative: What Would Justify Today's Price?

Narratives pick up where the DCF puzzle for Bio-Techne leaves off by spelling out which paths for revenue growth, profitability and earnings would need to play out for the shares to be worth materially more or less than today’s level on Simply Wall St’s Community page. Rather than leaning on a single ratio or model output, each Narrative lays out its own fair value assumptions so you can line those expectations up against actual results as they come through.

Bio-Techne investors on the Simply Wall St Community split between those who see more upside in the story and those who think expectations already look full.

Bull case: roughly fairly valued

"Rapid growth in Bio-Techne’s spatial biology portfolio, with mid teens growth and COMET revenue up more than 65% alongside a record backlog…"

Discover why this Narrative puts Bio-Techne at roughly fairly valued.

Bear case: 28% overvalued

"The numbers imply that Bio-Techne’s share price already reflects a successful recovery and a full takeover premium following Merck KGaA’s agreed all-cash offer at US$73 per share…"

Explore why this Narrative puts Bio-Techne at 28% overvalued.

Bio-Techne’s price is only one side of your decision

The cash flow story for Bio-Techne matters, but the people setting priorities and how they are rewarded can tilt outcomes in ways a model cannot capture. See who runs Bio-Techne and how they are paid.